50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Sell every Stock except ONE (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Sell every Stock except ONE (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Sell every Stock except ONE (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Sell every Stock except ONE (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
NASDAQ:VRNA

Verona Pharma - VRNA Stock Forecast, Price & News

$8.63
-0.73 (-7.80%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.61
$9.11
50-Day Range
$5.38
$13.59
52-Week Range
$3.41
$14.69
Volume
220,778 shs
Average Volume
299,237 shs
Market Capitalization
$628.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.75

Verona Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
233.1% Upside
$28.75 Price Target
Short Interest
Healthy
1.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.19mentions of Verona Pharma in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$1.10 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.33) to ($1.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

423rd out of 1,080 stocks

Pharmaceutical Preparations Industry

189th out of 535 stocks

VRNA stock logo

About Verona Pharma (NASDAQ:VRNA) Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Stock News Headlines

Verona Pharma (NASDAQ:VRNA) Stock Rating Reaffirmed by Wedbush
Verona Pharma (NASDAQ:VRNA) Shares Gap Down to $10.80
Dow Drops Over 100 Points; Verona Pharma Shares Jump
Recap: Verona Pharma Q2 Earnings
Why Verona Pharma Stock Is Skyrocketing Today
See More Headlines
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Company Calendar

Last Earnings
8/09/2022
Today
9/24/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRNA
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.75
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+233.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-55,570,000.00
Pretax Margin
-136.94%

Debt

Sales & Book Value

Annual Sales
$40 million
Book Value
$2.47 per share

Miscellaneous

Free Float
69,930,000
Market Cap
$628.01 million
Optionable
Not Optionable
Beta
0.46

Key Executives

  • Dr. David S. ZaccardelliDr. David S. Zaccardelli (Age 57)
    Pres, CEO & Exec. Director
    Comp: $627.27k
  • Mr. Mark W. HahnMr. Mark W. Hahn (Age 59)
    Chief Financial Officer
    Comp: $639.08k
  • Dr. Kathleen A. Rickard (Age 64)
    Chief Medical Officer
    Comp: $562.38k
  • Ms. Claire Louise Poll L.C.S.W. (Age 55)
    B.A., B Juris, LLB, ASIA, Gen. Counsel
  • Ms. Victoria Stewart
    Director of Communications
  • Mr. Matthew Casbon
    VP of Sales, Marketing & Training
  • Dr. Peter Spargo (Age 60)
    Sr. VP of Chemistry Manufacturing & Controls
  • Dr. Tara Rheault M.P.H. (Age 45)
    Ph.D., Sr. VP of R&D
  • Ms. Nina Church
    Exec. Director of Global Clinical Devel.
  • Mr. Christopher Martin
    Sr. VP of Commercial













VRNA Stock - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings
or view top-rated stocks.

What is Verona Pharma's stock price forecast for 2022?

4 Wall Street analysts have issued 12-month price targets for Verona Pharma's stock. Their VRNA share price forecasts range from $27.00 to $31.00. On average, they predict the company's stock price to reach $28.75 in the next twelve months. This suggests a possible upside of 233.1% from the stock's current price.
View analysts price targets for VRNA
or view top-rated stocks among Wall Street analysts.

How have VRNA shares performed in 2022?

Verona Pharma's stock was trading at $6.72 on January 1st, 2022. Since then, VRNA shares have increased by 28.4% and is now trading at $8.63.
View the best growth stocks for 2022 here
.

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VRNA earnings forecast
.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) issued its earnings results on Tuesday, August, 9th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Woodline Partners LP (0.82%), Ikarian Capital LLC (0.50%), D.A. Davidson & CO. (0.07%), Renaissance Technologies LLC (0.05%), Forefront Analytics LLC (0.05%) and Goldman Sachs Group Inc. (0.02%). Insiders that own company stock include Anders Ullman, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn and Patrick John Finn.
View institutional ownership trends
.

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $8.63.

How much money does Verona Pharma make?

Verona Pharma (NASDAQ:VRNA) has a market capitalization of $628.01 million and generates $40 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.

This page (NASDAQ:VRNA) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.